Sustained efficacy of secukinumab in patients with moderate‐to‐severe palmoplantar psoriasis: 2·5‐year results from GESTURE , a randomized, double‐blind, placebo‐controlled trial-Reference-Cited by-同舟云学术

Sustained efficacy of secukinumab in patients with moderate‐to‐severe palmoplantar psoriasis: 2·5‐year results from GESTURE , a randomized, double‐blind, placebo‐controlled trial

Published:2019-12-15 Issue:4 Volume:182 Page:889-899
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Gottlieb A.B.¹,Kubanov A.²,Doorn M.³,Sullivan J.⁴,Papp K.A.⁵^ORCID,You R.⁶,Regnault P.⁷,Frueh J.A.⁷

Affiliation:

1. Department of Dermatology Icahn School of Medicine at Mount Sinai New York NY U.S.A.

2. State Scientific Center of Dermatology, Venereology and Cosmetology Moscow Russia

3. Department of Dermatology Erasmus University Medical Center Rotterdam the Netherlands

4. Kingsway Dermatology & Aesthetics Miranda Australia

5. K. Papp Research and Probity Medical Research, Inc. Waterloo ON Canada

6. China Novartis Institutes for BioMedical Research Shanghai China

7. Novartis Pharma AG Basel Switzerland

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.18331

Reference26 articles.

1. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study

2. The use of methotrexate, alone or in combination with other therapies, for the treatment of palmoplantar psoriasis;Wald JM;J Drugs Dermatol,2015

3. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice

4. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)

5. Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience;Journal of Personalized Medicine;2024-07-03

2. A Real-Life 208 Week Single-Centred, Register-Based Retrospective Study Assessing Secukinumab Survival and Long-Term Efficacy and Safety Among Greek Patients With Moderate to Severe Plaque Psoriasis, Including Difficult-to-Treat Manifestations Such as Genitals and Scalp;Dermatology Practical & Conceptual;2024-04-30

3. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence;Autoimmunity Reviews;2024-04

4. Biologics: Beyond the Basics;Psoriasis - Recent Advances in Diagnosis and Treatment;2024-02-21

5. A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS);Dermatologic Therapy;2023-11-01